Core Viewpoint - Silver诺医药-B (02591) has seen a significant stock price increase of over 24% despite a previous decline of more than 25% in the two days following its inclusion in the Stock Connect program, indicating a positive market reaction to recent announcements [1] Group 1: Stock Performance - As of the latest update, the stock price of Silver诺医药-B is reported at 39.44 HKD, reflecting a rise of 23.38% with a trading volume of 76.49 million HKD [1] Group 2: Inclusion in Stock Connect - The company announced that its H shares have been included in the eligible securities list for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, effective from December 8, 2025 [1] - The board believes that this inclusion will expand the investor base and increase the trading liquidity of H shares, thereby enhancing the investment value and market reputation of the company [1] Group 3: Product Development - Silver诺医药-B has announced that its self-developed long-acting GLP-1 receptor agonist, Irsuglutide α (怡诺轻), has been officially included in the National Medical Insurance Drug List for 2025, set to be implemented from January 1, 2026 [1] - Irsuglutide α (怡诺轻) is characterized by a long half-life, low dosing frequency, and glucose-dependent regulation, making it the third globally and the first in Asia to enter the commercialization stage among long-acting GLP-1 receptor agonists [1] - This product is also noted as the first innovative drug of its kind developed in China, providing high-quality treatment options for type 2 diabetes patients [1]
银诺医药-B逆市拉升逾24% 近日公司正式入通 GLP-1受体激动剂怡诺轻 成功入保